On June 16, 2025 Immumem Therapeutics, an emerging biotechnology company focused on developing novel oncology therapeutics, reported it has been awarded a $75,000 non-dilutive grant from ScaleReady’s G-Rex Grant Program (Press release, Immumem Therapeutics, JUN 16, 2025, View Source [SID1234656571]). This funding will support the advancement of Immumem’s innovative manufacturing processes for next-generation cell therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The competitive grant provides Immumem with critical resources to expand its research platform and accelerate development timelines in the cell and gene therapy space. The award package includes access to advanced bioreactor technology, specialized reagents, and expert consulting services designed to enhance the company’s pre-clinical development capabilities.
"This non-dilutive funding represents a significant opportunity to accelerate our cell therapy manufacturing capabilities while preserving shareholder value," stated a spokesperson for Immumem Therapeutics. "The support from ScaleReady’s G-Rex Grant Program will enable us to optimize our production processes and advance our therapeutic pipeline toward key developmental milestones."
The G-Rex Grant Program is specifically designed to foster innovation within the cell and gene therapy sector by providing promising biotechnology companies with the resources needed to overcome manufacturing challenges and accelerate therapeutic development.
Immumem Therapeutics will utilize the grant to further refine its proprietary cell therapy manufacturing platform, with the goal of improving production efficiency and therapeutic potency. This advancement aligns with the company’s mission to develop more effective and accessible treatments for patients with cancer and other serious diseases.
For more information about Immumem Therapeutics and its development programs, please visit www.immumemtx.com or the company’s knowledge center.